The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study

Recruiting now

Conditions studied: Colorectal Cancer

In brief

This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.

Key facts

Study ID

NCT06136949

Run by

Centro di Riferimento Oncologico - Aviano

People needed

150

Starts

2023-05-22

Expected to finish

2032-12-31

Last updated by the study team

2023-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage.
• Age ≥18 years.
• Signed informed consent form.
• Availability of tissue and blood samples stored at the Institutional Biobank for research purposes.

You may not qualify if…

• Patients for which the tumour biobanking process could compromise the diagnostic assessments.
• Pregnancy or breast-feeding.
• History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.

Where it is running

• Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS — Aviano, Pordenone, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.